Merkel Cell Carcinoma Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | MacroGenics, TuHURA Biosciences, Philogen, Merus N.V., Kartos Therapeutics, Immunomic Therapeutics, Neoimmunetech, EMD Serono Researc

DelveInsight's "Merkel Cell Carcinoma Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Merkel Cell Carcinoma, historical and forecasted epidemiology, as well as the Merkel Cell Carcinoma market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

To know in detail about the Merkel Cell Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Merkel Cell Carcinoma Market Forecast- https://www.delveinsight.com/sample-request/merkel-cell-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Some of the key facts of the Merkel Cell Carcinoma Market Report:
• The Merkel Cell Carcinoma market size was valued ~USD 411 million in 2023 and is anticipated to grow with a significant CAGR of 8.7% during the study period (2020-2034)
• In 2023, the MCC market in the US was valued at approximately USD 180 million, accounting for 44% of the total market. This value is expected to rise substantially with the launch of new therapies.
• In 2023, the EU4 and the UK had an estimated market size of approximately USD 220 million, contributing nearly 54% of the total market revenue across the 7MM.
• In 2023, Germany had the highest market share among the EU4 and the UK, reaching approximately USD 65 million, followed by France at around USD 50 million, while Spain recorded the smallest share at nearly USD 20 million.
• In 2023, Japan's MCC market was valued at approximately USD 9 million, with projections indicating growth throughout the forecast period (2024-2034).
• Estimates show that among the currently available drugs, BAVENCIO (avelumab) as a first-line therapy captured the largest market share, generating around USD 290 million in revenue across the 7MM in 2023.
• In 2023, the US recorded the highest number of incident cases of MCC, totaling around 3,000. This figure is projected to rise by 2034, with a CAGR of 5%.
• In 2023, Germany had the highest incidence of MCC cases among the EU4 and the UK, reporting around 1,700 cases. France ranked second with approximately 1,300 cases, while Spain recorded the lowest incidence, with nearly 600 cases.
• In 2023, Japan recorded around 90 incident MCC cases in males and 140 in females, with the numbers expected to increase by 2034.
• In 2023, males comprised 51% of MCC cases in the EU4 and the UK, while females accounted for 49%. These gender distribution trends are expected to continue, with the overall incidence anticipated to rise by 2034.
• In the EU4 and the UK, around 80% of MCC cases in 2023 were attributed to MCPyV, while 20% were associated with UV damage, highlighting MCPyV as the leading cause.
• In 2023, Germany recorded around 700 cases of Stage I MCC, approximately 200 cases of Stage II, 600 cases of Stage III, and 140 cases of Stage IV. These figures are projected to rise by 2034.
• Merkel Cell Carcinoma Companies such as MacroGenics, TuHURA Biosciences, Philogen, Merus N.V., Kartos Therapeutics, Immunomic Therapeutics, Neoimmunetech, EMD Serono Research, Merck Sharp & Dohme, Millennium Pharmaceutical, Bristol-Myers Squibb, Incyte Corporation, Immune Oncology Network, Sotio Biotech Inc, Regeneron Pharmaceuticals, and others
• Merkel Cell Carcinoma Therapies such as BAVENCIO (avelumab), ZYNYZ (retifanlimab-dlwr), KEYTRUDA (pembrolizumab), IFx-2.0, NIDLEGY (L19-IL2/L19-TNF), MCLA 145, Navtemadlin (KRT-232), ITI-3000, NT-I7 (efineptakinalfa), Avelumab, Pembrolizumab, MLN0128, Nivolumab, KRT-232, Retifanlimab, NT-I7, CAR-GPC3 T Cells, vidutolimod, and others

Discover which therapies are expected to grab the Merkel Cell Carcinoma Market Share @ Merkel Cell Carcinoma Market Outlook- https://www.delveinsight.com/sample-request/merkel-cell-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Merkel Cell Carcinoma Epidemiology Segmentation in the 7MM
• Total Prevalence of Merkel Cell Carcinoma
• Prevalent Cases of Merkel Cell Carcinoma by severity
• Gender-specific Prevalence of Merkel Cell Carcinoma
• Diagnosed Cases of Episodic and Chronic Merkel Cell Carcinoma

Download the report to understand which factors are driving Merkel Cell Carcinoma epidemiology trends @ Merkel Cell Carcinoma Epidemiology Forecast- https://www.delveinsight.com/sample-request/merkel-cell-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Merkel Cell Carcinoma Marketed Drugs
• BAVENCIO (avelumab): Merck KGaA
BAVENCIO is a human monoclonal antibody that targets PD-L1, administered intravenously. It works by binding to PD-L1, preventing tumor cells from using this protein to evade immune detection, thus enhancing the immune system's ability to attack and eliminate cancer cells. BAVENCIO also induces antibody-dependent cell-mediated cytotoxicity (ADCC) in lab studies. Its significant antitumor effects led to its approval as a first-line treatment for metastatic Merkel Cell Carcinoma. It is approved in the US, Europe, and Japan for this indication.

• ZYNYZ (retifanlimab-dlwr): Incyte Corporation/MacroGenics
ZYNYZ (retifanlimab-dlwr) is a sterile, preservative-free solution for IV use, appearing as a clear to slightly opalescent, colorless to pale yellow liquid. It is a PD-1-blocking antibody approved under accelerated approval in the US for treating adult patients with metastatic or recurrent locally advanced Merkel Cell Carcinoma, based on tumor response rate and duration. ZYNYZ is approved in both the US and Europe and has received Orphan Drug Designation (ODD) and Fast Track Designation (FTD).

• KEYTRUDA (pembrolizumab): Merck
KEYTRUDA (pembrolizumab) is an anti-PD-1 therapy that boosts the immune system's ability to fight tumor cells. As a humanized monoclonal antibody, it blocks PD-1's interaction with PD-L1 and PD-L2, activating T lymphocytes. It is supplied as a sterile, preservative-free IV solution. KEYTRUDA was approved based on the CITN-09/KEYNOTE-017 and KEYNOTE-913 studies and is approved in the US, with ODD and Breakthrough Therapy Designation (BTD).

Merkel Cell Carcinoma Emerging Drugs
• IFx-2.0: TuHURA Biosciences
IFx-2.0, developed by TuHURA Biosciences, activates the innate immune system to target tumors by injecting plasmid DNA encoding a bacterial protein into the cancer, making it appear as a foreign pathogen. TuHURA plans a Phase III trial combining IFx-2.0 with KEYTRUDA for first-line treatment of advanced Merkel Cell Carcinoma, starting in 2025 under an SPA agreement with the FDA.

• NIDLEGY (L19-IL2/L19-TNF): Philogen
NIDLEGY, developed by Philogen, combines L19-IL2 and L19-TNF to target the Fibronectin B domain, found in tumors but rarely in healthy tissue. L19-IL2 enhances immune activation, while L19-TNF aids in tumor destruction. This dual approach shows promise for treating Merkel Cell Carcinoma with fewer side effects and is currently in Phase II for patients with unresectable or metastatic Merkel Cell Carcinoma.

• MCLA 145: Merus N.V.
MCLA-145 is a novel Biclonics T-cell agonist targeting both PD-L1 and CD137, showing potential for treating Merkel Cell Carcinoma. In preclinical models, it attracts T cells into tumors, activates immune cells, and blocks inhibitory signals, enhancing immune response. A Phase I study tested MCLA-145 alone and with pembrolizumab in advanced or metastatic cancers, including Merkel Cell Carcinoma, highlighting its potential in future trials.

To learn more about Merkel Cell Carcinoma treatment guidelines, visit @ Merkel Cell Carcinoma Treatment Market Landscape- https://www.delveinsight.com/sample-request/merkel-cell-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Merkel Cell Carcinoma Therapies and Companies
• BAVENCIO (avelumab): Merck KGaA
• ZYNYZ (retifanlimab-dlwr): Incyte Corporation/MacroGenics
• KEYTRUDA (pembrolizumab): Merck
• IFx-2.0: TuHURA Biosciences
• NIDLEGY (L19-IL2/L19-TNF): Philogen
• MCLA 145: Merus N.V.
• Navtemadlin (KRT-232): Kartos Therapeutics
• ITI-3000: Immunomic Therapeutics
• NT-I7 (efineptakinalfa): Neoimmunetech
• Avelumab: EMD Serono Research
• Pembrolizumab: Merck Sharp & Dohme
• MLN0128: Millennium Pharmaceutical
• Nivolumab: Bristol-Myers Squibb
• KRT-232: Kartos Therapeutics
• Retifanlimab: Incyte Corporation
• NT-I7: Immune Oncology Network
• CAR-GPC3 T Cells: Sotio Biotech Inc
• vidutolimod: Regeneron Pharmaceuticals

Merkel Cell Carcinoma Drugs Market Insights
Merkel Cell Carcinoma treatment primarily involves surgery as the first-line therapy, often combined with radiation or chemotherapy for patients who do not respond adequately. Immunotherapy, such as PD-1/PD-L1 inhibitors, may also be used for advanced or metastatic cases to enhance the immune response against the tumor. Emerging therapies include IFx-2.0, NIDLEGY (L19-IL2/L19-TNF), and MCLA 145.

Merkel Cell Carcinoma Market Outlook
Merkel Cell Carcinoma is characterized by rapid growth, high metastatic potential, and poor survival, especially in advanced stages. Treatment strategies depend on disease stage and individual factors. Surgery and radiation remain essential for localized Merkel Cell Carcinoma, while systemic therapies, particularly immunotherapy, have transformed the approach to advanced Merkel Cell Carcinoma, improving patient outcomes in these cases.

Learn more about the FDA-approved drugs for Merkel Cell Carcinoma @ Drugs for Merkel Cell Carcinoma Treatment- https://www.delveinsight.com/sample-request/merkel-cell-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Merkel Cell Carcinoma Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Merkel Cell Carcinoma Companies: MacroGenics, TuHURA Biosciences, Philogen, Merus N.V., Kartos Therapeutics, Immunomic Therapeutics, Neoimmunetech, EMD Serono Research, Merck Sharp & Dohme, Millennium Pharmaceutical, Bristol-Myers Squibb, Kartos Therapeutics, Incyte Corporation, Immune Oncology Network, Sotio Biotech Inc, Regeneron Pharmaceuticals, and others
• Merkel Cell Carcinoma Therapies: BAVENCIO (avelumab), ZYNYZ (retifanlimab-dlwr), KEYTRUDA (pembrolizumab), IFx-2.0, NIDLEGY (L19-IL2/L19-TNF), MCLA 145, Navtemadlin (KRT-232), ITI-3000, NT-I7 (efineptakinalfa), Avelumab, Pembrolizumab, MLN0128, Nivolumab, KRT-232, Retifanlimab, NT-I7, CAR-GPC3 T Cells, vidutolimod, and others
• Merkel Cell Carcinoma Therapeutic Assessment: Merkel Cell Carcinoma current marketed and Merkel Cell Carcinoma emerging therapies
• Merkel Cell Carcinoma Market Dynamics: Merkel Cell Carcinoma market drivers and Merkel Cell Carcinoma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Merkel Cell Carcinoma Unmet Needs, KOL's views, Analyst's views, Merkel Cell Carcinoma Market Access and Reimbursement

To know more about Merkel Cell Carcinoma companies working in the treatment market, visit @ Merkel Cell Carcinoma Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/merkel-cell-carcinoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Merkel Cell Carcinoma Market Report Introduction
2. Executive Summary for Merkel Cell Carcinoma
3. SWOT analysis of Merkel Cell Carcinoma
4. Merkel Cell Carcinoma Patient Share (%) Overview at a Glance
5. Merkel Cell Carcinoma Market Overview at a Glance
6. Merkel Cell Carcinoma Disease Background and Overview
7. Merkel Cell Carcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Merkel Cell Carcinoma
9. Merkel Cell Carcinoma Current Treatment and Medical Practices
10. Merkel Cell Carcinoma Unmet Needs
11. Merkel Cell Carcinoma Emerging Therapies
12. Merkel Cell Carcinoma Market Outlook
13. Country-Wise Merkel Cell Carcinoma Market Analysis (2020-2034)
14. Merkel Cell Carcinoma Market Access and Reimbursement of Therapies
15. Merkel Cell Carcinoma Market Drivers
16. Merkel Cell Carcinoma Market Barriers
17. Merkel Cell Carcinoma Appendix
18. Merkel Cell Carcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

List of Top Selling Market Research Reports in 2025

Biopsy devices market- https://www.delveinsight.com/report-store/biopsy-devices-market
Diabetic wound market - https://www.delveinsight.com/report-store/diabetic-wounds-market
Joint reconstruction devices market- https://www.delveinsight.com/report-store/joint-reconstruction-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cystic fibrosis market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Heart failure market- https://www.delveinsight.com/report-store/congestive-heart-failure-market
NK Cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Positive airway pressure device market - https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Uterine fibroids market- https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-market
Attention deficit hyperactivity disorder adhd market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
Lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.